Skip to main content
SpringerLink
Log in

Lerisetron

F 0930, F 0930RS

  • Section 1: Antiemetics in Oncology
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lukas J, Calvo R, Jaureguizar N, et al. Lerisetron pk-pd in vivo: experimental results and comparison with a pharmacokinetic (unbound concentration) pharmacodynamic theory [abstract]. Br J Pharmacol 1998 Jul; 124 Suppl.: 5P

    Article  Google Scholar 

  2. Calvo R, Jiménez RM, Trocóniz IF, et al. Serum protein binding of lerisetron, a novel specific 5HT3 antagonist, in patients with cancer. Cancer Chemother Pharmacol 1998 Oct; 42: 418–22

    Article  PubMed  CAS  Google Scholar 

  3. Orjales A, Mosquera R, Labeaga L, et al. New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists: synthesis and pharmacological evaluation. J Med Chem 1997 Feb 14; 40: 586–93

    Article  PubMed  CAS  Google Scholar 

  4. Zamacona MK, Raczka E, Valle M, et al. Dose-response relationship and time-course of the in vivo 5-HT3 receptor antagonism by lerisetron. Methods Find Exper Clin Pharmacol 1997; 19 Suppl. A: 103

    Google Scholar 

  5. Corcostegui R, Labeaga L, Orjales A. Lerisetron: a new potent, selective and long acting 5-HT3 receptor antagonist. Methods Find Exper Clin Pharmacol 1997; 19 Suppl. A: 103

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lerisetron. Drugs R&D 2, 245–246 (1999). https://doi.org/10.2165/00126839-199902040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902040-00005

Keywords

Search

Navigation